Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Qingtang Lin"'
Autor:
Ye Cheng, Lei Zhang, Xiaolong Wu, Hiroaki Wakimoto, Haoming Geng, Yukui Wei, Geng Xu, Xinru Xiao, Jie Bai, Yaming Wang, Zeliang Hu, Leiming Wang, Qingtang Lin
Publikováno v:
Genes and Diseases, Vol 11, Iss 1, Pp 53-56 (2024)
Externí odkaz:
https://doaj.org/article/66f8ae437cf040b6a8265a881753a8ac
Autor:
Xu Wang, Mingchu Li, Xinru Xiao, Ge Chen, Jie Tang, Qingtang Lin, Hongchuan Guo, Gang Song, Xiaolong Wu, Yuhai Bao, Jiantao Liang
Publikováno v:
Chinese Neurosurgical Journal, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Background Total removal of the vestibular schwannoma when preserving the function of the facial nerve is difficult. The objective of the current study was to investigate the short-term clinical outcome of vestibular schwannoma removal via r
Externí odkaz:
https://doaj.org/article/83ce4d23aa2744afa0966e4f20025b43
Autor:
Xiaolong Wu, Xu Wang, Gang Song, Mingchu Li, Chengbei Hou, Ge Chen, Hongchuan Guo, Xinru Xiao, Jie Tang, Qingtang Lin, Yuhai Bao, Jiantao Liang
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background There is an ongoing discussion about the advantages and disadvantages of different surgical positions (semi-sitting and lateral position) for vestibular schwannoma surgery. Each position has its advantages, disadvantages, challeng
Externí odkaz:
https://doaj.org/article/b5a624021e064af990c2023a7552fb6b
Autor:
Ye Cheng, Shuangshuang Song, Yukui Wei, Geng Xu, Yang An, Jie Ma, Hongwei Yang, Zhigang Qi, Xinru Xiao, Jie Bai, Lixin Xu, Zeliang Hu, Tingting Sun, Leiming Wang, Jie Lu, Qingtang Lin
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Gliomas exhibit high intra-tumoral histological and molecular heterogeneity. Introducing stereotactic biopsy, we achieved a superior molecular analysis of glioma using O-(2-18F-fluoroethyl)-L-tyrosine (FET)-positron emission tomography (PET) and diff
Externí odkaz:
https://doaj.org/article/afb6ad53118f460eb0b9a11a83082980
Autor:
Qingtang Lin, Teer Ba, Jinyuan Ho, Dandan Chen, Ye Cheng, Leiming Wang, Geng Xu, Lixin Xu, Yiqiang Zhou, Yukui Wei, Jianqiang Li, Feng Ling
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Glioblastoma is the most common primary brain malignancy with limited treatment options. EphA2 is a tumor-associated-antigen overexpressed in glioblastoma. Pre-clinical studies have demonstrated the promise of EphA2-redirected CAR T-cells against gli
Externí odkaz:
https://doaj.org/article/aeff9c3877fc419fb85c72d02b729e59
Autor:
Sun-Jin Kim, Jang-Seong Kim, Eun Sung Park, Ju-Seog Lee, Qingtang Lin, Robert R. Langley, Marva Maya, Junqin He, Seung-Wook Kim, Zhang Weihua, Krishnakumar Balasubramanian, Dominic Fan, Gordon B. Mills, Mien-Chie Hung, Isaiah J. Fidler
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 13, Iss 3, Pp 286-298 (2011)
In the United States, more than 40% of cancer patients develop brain metastasis. The median survival for untreated patients is 1 to 2 months, which may be extended to 6 months with conventional radiotherapy and chemotherapy. The growth and survival o
Externí odkaz:
https://doaj.org/article/298f851c3462484aa6d1fece1afde524
Autor:
Qingtang Lin, Krishnakumar Balasubramanian, Dominic Fan, Sun-Jin Kim, Lixia Guo, Hua Wang, Menashe Bar-Eli, Kenneth D. Aldape, Isaiah J. Fidler
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 12, Iss 9, Pp 748-754 (2010)
Brain metastases are highly resistant to chemotherapy. Metastatic tumor cells are known to exploit the host microenvironment for their growth and survival. We report here that melanoma brain metastases are surrounded and infiltrated by activated astr
Externí odkaz:
https://doaj.org/article/3983dfad37874a64b14cde2803962811
Autor:
Ye Cheng, Lei Zhang, Xiaolong Wu, Hiroaki Wakimoto, Haoming Geng, Yukui Wei, Geng Xu, Xinru Xiao, Jie Bai, Yaming Wang, Zeliang Hu, Leiming Wang, Qingtang Lin
Publikováno v:
Genes & Diseases.
Autor:
Qingtang Lin, Guoguang Zhao, Lan Zhang, Xinxia Li, Xiaobao Chen, Chaoying Hu, Chuan Liu, Jacqueline Ming Liu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 86:793-801
Temozolomide is an alkylating agent approved by the U.S. Food and Drug Administration in 1999 for the treatment of patients with primary brain tumors. The aim of this study was to confirm the bioequivalence and safety of two strengths (20–100 mg) o